目的 探讨宫瘤消胶囊联合地诺孕素治疗子宫内膜异位症的临床疗效。方法 选取2023年6月—2025年4月中国人民解放军联勤保障部队第九七〇医院收治的100例子宫内膜异位症患者，按照随机数字法分为对照组和治疗组，每组50例。对照组口服地诺孕素片，1片/次，1次/d。治疗组患者在对照组的治疗基础上口服宫瘤消胶囊，3～4粒/次，3次/d。两组均连续治疗3个月经周期。观察两组的临床疗效，比较两组Kupperman评分、COX痛经症状评分量表（CMSS）、卵泡刺激素（FSH）、黄体生成素（LH）、雌二醇（E₂）、血清血管内皮生长因子（VEGF）、甲壳质酶蛋白40（YKL-40）、基质金属蛋白酶9（MMP-9）、血清巨噬细胞移动抑制因子（MMIF）水平。结果 治疗后，治疗组总有效率（96.00%）显著高于对照组（82.00%）。治疗后，两组CMSS、Kupperman评分与治疗前比较均降低（P＜0.05），且与对照组对比，治疗组的CMSS、Kupperman评分更低（P＜0.05）。治疗后，两组患者LH、FSH、E₂水平与治疗前比较均下降（P＜0.05），且与对照组对比，治疗组LH、FSH、E₂水平更低（P＜0.05）。治疗后，两组VEGF、YKL-40、MMP-9、MMIF水平均低于治疗前（P＜0.05）；且治疗后，与对照组对比，治疗组患者的VEGF、YKL-40、MMP-9、MMIF水平均较低（P＜0.05）。结论 宫瘤消胶囊联合地诺孕素治疗子宫内膜异位症患者临床疗效显著，能减轻疼痛，并能抑制内膜异位组织的生长，调节患者性激素和血清炎性因子水平。

Objective To investigate the clinical efficacy of Gongliuxiao Capsules combined with dienogest in treatment of endometriosis. Methods From June 2023 to April 2025, 100 patients with endometriosis who were admitted to the 970th Hospital of Joint Logistics Support Force were selected. They were randomly divided into control group and treatment group, with 50 cases in each group. Patients in control group were given oral Dienogest Tablets, 1 tablet/time, once daily. Patients in treatment group were given Gongliuxiao Capsules in addition to treatment of control group, 3—4 capsules/time, 3 times daily. Both groups were treated continuously for 3 menstrual cycles. The clinical efficacy of two groups was observed, and the Kupperman score, CMSS score, FSH, LH, E₂, VEGF, YKL-40, MMP-9, and MMIF levels were compared between two groups. Results After treatment, the total effective rate of the treatment group (96.00%) was significantly higher than that of control group (82.00%). After treatment, the CMSS and Kupperman scores of both groups decreased compared with those before treatment (P < 0.05), and compared with control group, the CMSS and Kupperman scores of treatment group were lower (P < 0.05). After treatment, the levels of LH, FSH, and E₂ in both groups decreased compared with those before treatment (P < 0.05), and compared with control group, the levels of LH, FSH, and E₂ in treatment group were lower (P < 0.05). After treatment, the levels of VEGF, YKL-40, MMP-9, and MMIF in both groups were lower than those before treatment (P < 0.05). And after treatment, compared with control group, the levels of VEGF, YKL-40, MMP-9, and MMIF in treatment group were lower (P < 0.05). Conclusion The clinical efficacy of Gongliuxiao Capsules combined with dienogest in treating patients with endometriosis is remarkable, and can alleviate pain, inhibit the growth of endometriotic tissues, and regulate the levels of sex hormones and serum inflammatory factors in patients.

R984

山东省医药卫生科技项目(202313010989)